ACI’s ‘Developments in Gene Expression Profiling’ Conference will address the challenges of developing and integrating the latest profiling techniques across drug discovery and development. Case studies will focus on the use of genetic profiling to create a personalised approach to treatment and in toxicology and safety assessment of candidates. The agenda will also focus on developments in RNAi and qPCR technologies whilst considering strategic issues such as cost of investment and factors affecting expansion of the gene expression market.

*The programme focuses on: *
> Widening the applications of gene expression profiling tools in drug discovery and development
> Supporting toxicology studies and safety assessment of drug candidates
> Working towards a personalised medicine approach – genetic profiling as a tool to determine treatment choices
> Focus on developments in RNAi – Evaluating RNAi delivery technology and applying RNAi for target identification and validation
> Applying real-time PCR (qPCR) in discovery and development studies
> Maximising discovery and development of biomarkers using gene expression profiling

*Who should attend? *
Attendees will be senior-level decision-makers, working within drug discovery and development, and biomarker discovery, drawn from pharmaceutical and biotech companies throughout Europe, and will include:
VPs, Directors and Senior Scientists of Gene Expression/Silencing/Profiling, Genomics, Pharmacogenomics/Pharmacology, Drug Discovery, Development, Clinical Research, Biomarkers, Translational/Experimental Medicine, Biology/Biologics, Toxicology, Toxicogenomics, Safety Sciences and Personalised Medicine